More than 240 immuno-oncology treatments in development to fight cancer

Andrew Powaleny   |     June 1, 2017   |   SHARE THIS


The American Cancer Society estimates that in 2017 alone, there will be more than 1.6 million new cases of cancer and 600,000 cancer deaths in the United States. With estimates like these, the need for new cancer treatments is more important than ever, and America’s biopharmaceutical companies are boldly leading the way in discovering new breakthroughs.

PhRMA, in partnership with the American Cancer Society Cancer Action Network (ACS CAN), announced today in a new report that there are more than 240 immuno-oncology medicines and vaccines in development to treat cancer. These immuno-oncology medicines, otherwise known as immunotherapies, are novel in the way they use the body’s own immune system to fight cancer, similar to how the immune system would attack a virus or bacteria.

There are multiple classes of innovative immunotherapies, and the report includes treatments in development in the most recognized classes, including adoptive cell therapies (including CAR-T therapy), bi-specific antibodies, cytokines, immune checkpoint modulators, oncolytic virus therapies and vaccines. It also details how researchers are working to understand the full potential of each individual medicine, seeking approval for new indications for existing immunotherapies and new uses in combination with other cancer medicines.

The report was released as part of PhRMA’s GOBOLDY campaign, which showcases the bold advancements the industry is making in tackling our most complex and devastating health conditions through innovative research. While the biopharmaceutical industry is a leader in the development of innovative treatments, it also plays a critical role along with others in the health care ecosystem to help bring new medicines to patients.

To learn more about the “Medicines in Development for Immuno-Oncology” report click here.

Andrew Powaleny

Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organization's scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.

Topics: Medicines in Development, Personalized Medicine, Cancer

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates